Anti-metastasis mAb assessment

Challenge: Alacrita was asked to assess a novel mAB-based approach to suppressing cancer metastases. The client, a biotech incubator with rights to the project, was considering further investment,...
Learn More

Commercial Supply Chain Planning

Challenge: Our client was a publicly-traded clinical-stage pharmaceutical company, which specialized in drug formulation and delivery technology innovation. Its lead development drug was an inhaled...
Learn More

Investor due diligence for a live biotherapeutic product

Challenge: A developer of live biotherapeutic products (LBP) derived from stool donations had a lead product in phase 2 clinical trials for metabolic pathology secondary to hepatic pathology. An...
Learn More

Due diligence on a computational chemistry software for a private equity firm

Challenge: A generalist private equity firm was considering an investment in a computational chemistry company, and required an evaluation of the company’s software suite as part of its due diligence...
Learn More

Out-licensing support for a dengue vaccine

Challenge A company was developing a unique dengue vaccine which it planned to out-license to a Big Pharma partner. Alacrita was commissioned to provide business development support to identify a...
Learn More

Rare disease landscape and acquisition screening

Challenge Our client, a mid-cap research-based pharmaceutical company, had enjoyed striking success with a rare disease product which had different market dynamics to the bulk of the company's...
Learn More

Regulatory support to understand likelihood of approval of an ophthalmology asset

Challenge: A European pharmaceutical company focussed on ophthalmic care was seeking Well Established Use (WEU) approval in Europe for a small molecule asset. The company commissioned Alacrita to...
Learn More

Validating the opportunity for a novel anticoagulant with KOL research

Challenge: A research-focused biotech company developing a novel, first-in-class, next generation oral anticoagulant for the prevention of life-threatening thrombotic events asked Alacrita to...
Learn More

Evaluating the attractiveness & potential positioning of a new kinase inhibitor

Challenge: An in-silico drug discovery company requested an expert review of the robustness and potential positioning of a new kinase inhibitor in oncology and inflammatory disease. Alacrita was...
Learn More

Due diligence on a series of investments in oncology and genetic diseases

Challenge: A European investor required due diligence support to appraise the attractiveness of a series of potential investments. The technologies included a theranostic agent, a DNA damage response...
Learn More

Valuation of an integrin-targeting oncology asset

Challenge A preclinical-stage company developing an integrin-targeting oncology asset engaged Alacrita to quantify the value potential of its lead asset in pancreatic ductal adenocarcinoma (PDAC),...
Learn More

Clinical and regulatory due diligence of an asset targeting pre-term birth complications

Challenge: Our client was a European mid-size pharmaceutical company considering an investment in a clinical-stage company developing an asset for multiple indications associated with pre-term birth...
Learn More